中国不同流行地区1992与2014年1~29岁人群乙型肝炎血清流行病学调查比较分析
基于1992年和2014年全国乙型肝炎血清流行病学调查,比较1~29岁人群HBsAg、抗-HBs和抗-HBc阳性率。2014年HBsAg阳性率2.64%较1992年10.13%下降73.92%,抗-HBs阳性率57.79%较1992年25.41%上升127.41%。乙型肝炎疫苗纳入免疫规划后出生人群(2002—2013年出生)在高、中、低流行区HBsAg阳性率均降至1%以下。
要点
- 2014年1~29岁人群HBsAg阳性率2.64%,较1992年10.13%下降73.92%。
- 乙型肝炎疫苗纳入免疫规划后出生人群HBsAg阳性率在高、中、低流行区均低于1%。
- 2014年抗-HBs阳性率57.79%,较1992年25.41%上升127.41%。
核心结论
- 中国乙型肝炎预防控制效果显著,2014年全国1~29岁人群HBsAg阳性率较1992年下降。
- 在不同流行地区乙型肝炎疫苗纳入免疫规划后出生人群HBsAg阳性率均已降至1%以下。
研究设计与样本
- 比较分析1992年和2014年全国乙型肝炎血清流行病学调查数据。
- 1992年调查覆盖内地30个省份145个疾病监测点,共调查1~29岁人群34 291名。
- 2014年调查覆盖内地31个省份160个疾病监测点,共调查1~29岁人群31 713名。
- 两次调查均采用入户或集中调查方式,采集静脉血5 ml检测HBsAg、抗-HBs、抗-HBc。
- 1992年计算样本数据阳性率及95%CI,2014年按设计权重加权估计阳性率及95%CI。
主要发现
- 2014年1~29岁人群HBsAg阳性率2.64%(95%CI:2.28%~3.06%),较1992年10.13%(95%CI:9.81%~10.45%)下降73.92%。
- 2014年抗-HBc阳性率13.01%(95%CI:12.09%~14.00%),较1992年45.84%(95%CI:45.31%~46.37%)下降71.61%。
- 2014年抗-HBs阳性率57.79%(95%CI:56.33%~59.25%),较1992年25.41%(95%CI:24.95%~25.87%)上升127.41%。
- 1992—2001年出生人群2014年高、中、低流行区HBsAg阳性率分别为4.74%(95%CI:3.79%~5.69%)、1.59%(95%CI:1.09%~2.10%)、2.53%(95%CI:1.66%~3.39%)。
- 2002—2013年出生人群2014年高、中、低流行区HBsAg阳性率分别为0.88%(95%CI:0.66%~1.11%)、0.37%(95%CI:0.24%~0.49%)、0.71%(95%CI:0.48%~0.94%)。
关键数值与推荐
- 1992—2001年出生人群2014年高、中、低流行区抗-HBs阳性率分别为64.25%(95%CI:62.11%~66.39%)、56.34%(95%CI:54.50%~58.57%)、54.49%(95%CI:51.75%~57.23%)。
- 1992—2001年出生人群2014年高、中、低流行区抗-HBc阳性率分别为15.16%(95%CI:13.56%~16.76%)、11.07%(95%CI:9.80%~12.33%)、7.61%(95%CI:6.15%~9.07%)。
- 2002—2013年出生人群2014年高、中、低流行区抗-HBs阳性率分别为60.74%(95%CI:59.57%~61.90%)、59.46%(95%CI:58.44%~60.49%)、52.56%(95%CI:51.20%~53.92%)。
- 2002—2013年出生人群2014年高、中、低流行区抗-HBc阳性率分别为3.30%(95%CI:2.87%~3.72%)、1.91%(95%CI:1.63%~2.20%)、2.25%(95%CI:1.85%~2.66%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the effect of hepatitis B prevention and control by comparative analysis on the results of HBsAg, anti-HBs and anti-HBc prevalence from national hepatitis B seroepidemiological surveys in 1992 and 2014 in different epidemic regions of China. Methods: Data was from the national seroepidemiological surveys of hepatitis B conducted in 1992 and 2014. The survey in 1992 was conducted in 145 disease surveillance points of 30 provinces (excluding Hong Kong, Macao Special Administrative Region and Taiwan province) in China. The survey in 2016 was conducted in 160 disease surveillance points of 31 provinces (excluding Hong Kong, Macao Special Administrative Region and Taiwan province) in China. In the two surveys, face-to-face interviews with the subject by door to door or on the investigation site were conducted by trained staff using standard questionnaires to obtain basic information including birth date, gender, ethnicity, resident place and so on. And then 5 ml venous blood was collected to test the sero-markers of HBsAg, anti-HBs and anti-HBc. We analyzed unweighted point prevalence and 95% CI of HBsAg, anti-HBs and anti-HBc in 1992 which had no design weighting, and analyzed weighted point prevalence and 95%CI of HBsAg, anti-HBs and anti-HBc in 2014 which had design weighting. Results: 34 291 and 31 713 people aged 1-29 years were involved in 1992 and 2014 national serosurveys of China, respectively. For the people aged 1-29 years, HBsAg prevalence was 2.64% (95%CI: 2.28%-3.06%) in 2014 and decreased by 73.92% as compared with the rate 10.13% (95% CI: 9.81%-10.45%) in 1992. Anti-HBc prevalence was 13.01% (95%CI: 12.09%-14.00%) in 2014 and decreased by 71.61% as compared with the rate 45.84% (95% CI: 45.31%-46.37%) in 1992. Anti-HBs prevalence was 57.79% (95%CI: 56.33%-59.25%) in 2014 and ascended by 127.41% as compared with the rate 25.41% (95% CI: 24.95%-25.87%) in 1992. In high, medium and low epidemic region, for the people who born during 1992-2001 when hepatitis B vaccine was introduced in routine immunization management, HBsAg prevalence was 4.74% (95%CI: 3.79%-5.69%), 1.59% (95%CI: 1.09%-2.10%) and 2.53% (95%CI: 1.66%-3.39%), respectively, and anti-HBs prevalence was 64.25% (95% CI: 62.11%-66.39%), 56.34% (95% CI: 54.50%-58.57%), 54.49% (95%CI: 51.75%-57.23%), respectively, and anti-HBc prevalence was 15.16% (95%CI: 13.56%-16.76%), 11.07% (95%CI: 9.80%-12.33%), 7.61% (95%CI: 6.15%-9.07%), respectively. In high, medium and low epidemic region, for the people who born during 2002-2013 the duration which hepatitis B vaccine was integrated in expanded immunization program born during when HBsAg prevalence was 0.88% (95%CI: 0.66%-1.11%), 0.37% (95%CI: 0.24%-0.49%)and 0.71% (95%CI: 0.48%-0.94%), respectively, and anti-HBs prevalence was 60.74% (95%CI: 59.57%-61.90%), 59.46% (95%CI: 58.44%-60.49%), 52.56% (95% CI: 51.20%-53.92%), respectively, and anti-HBc prevalence was 3.30% (95% CI: 2.87%-3.72%), 1.91% (95%CI: 1.63%-2.20%), 2.25% (95%CI: 1.85%-2.66%), respectively. Conclusion: China had made great achievement in hepatitis B prevention and control. HBsAg prevalence among people aged 1-29 years old in 2014 decreased dramatically as compared with that in 1992. Since hepatitis B vaccine was integrated into expanded immunization program, China reduced HBsAg prevalence to less than 1% among people aged 1-12 years in 2014 in different epidemic region. 目的: 分析比较中国1992和2014年不同流行地区1~29岁人群乙型肝炎血清学指标阳性率,评价乙型肝炎预防控制效果。 方法: 数据来自于1992年全国病毒性肝炎血清流行病学调查和2014年全国乙型肝炎血清流行病学调查数据。1992年调查覆盖内地30个省份(不包括中国香港、澳门、台湾数据)145个疾病监测点;2014年调查覆盖内地31个省份(不包括中国香港、澳门、台湾数据)160个疾病监测点。两次调查均采用入户或集中调查的方式,问卷调查内容包括出生日期、性别、民族、地区等。问卷调查后,采集静脉血5 ml,检测HBsAg、抗-HBs、抗-HBc。1992年调查数据计算相关指标阳性率及其95%CI值为样本数据;2014年调查按设计权重加权估计相关指标阳性率及其95%CI值。 结果: 1992年共调查1~29岁人群34 291名,2014年为31 713名。2014年HBsAg阳性率为2.64%(95%CI:2.28%~3.06%),较1992年(10.13%,95%CI:9.81%~10.45%)下降73.92%;2014年抗-HBc阳性率为13.01%(95%CI:12.09%~14.00%),较1992年(45.84%,95%CI:45.31%~46.37%)下降71.61%;2014年抗-HBs阳性率为57.79%(95% CI:56.33%~59.25%),较1992年(25.41%,95% CI:24.95%~25.87%)上升127.41%。乙型肝炎疫苗纳入计划免疫管理后出生人群(即1992—2001年出生),2014年高、中、低流行区该人群HBsAg阳性率分别为4.74%(95%CI:3.79%~5.69%)、1.59%(95%CI:1.09%~2.10%)、2.53%(95% CI:1.66%~3.39%),抗-HBs阳性率分别为64.25%(95% CI:62.11%~66.39%)、56.34%(95%CI:54.50%~58.57%)、54.49%(95%CI:51.75%~57.23%),抗-HBc阳性率分别为15.16%(95%CI:13.56%~16.76%)、11.07%(95%CI:9.80%~12.33%)、7.61%(95%CI:6.15%~9.07%)。乙型肝炎疫苗纳入免疫规划后出生人群(即2002—2013年出生),2014年高、中、低流行区HBsAg阳性率分别为0.88%(95% CI:0.66%~1.11%)、0.37%(95% CI:0.24%~0.49%)、0.71%(95% CI:0.48%~0.94%),抗-HBs阳性率分别为60.74%(95%CI:59.57%~61.90%)、59.46%(95%CI:58.44%~60.49%)、52.56%(95%CI:51.20%~53.92%),抗-HBc阳性率分别为3.30%(95%CI:2.87%~3.72%)、1.91%(95%CI:1.63%~2.20%)、2.25%(95%CI:1.85%~2.66%)。 结论: 中国乙型肝炎预防控制效果显著,2014年全国1~29岁人群HBsAg阳性率较1992年下降,在不同流行地区乙型肝炎疫苗纳入免疫规划后出生人群HBsAg阳性率均已降至1%以下。.
引用
- Wang FZ, Zhang GM, Shen LP, et al. [Comparative analyze on hepatitis B seroepidemiological surveys among population aged 1-29 years in different epidemic regions of China in 1992 and 2014]. Zhonghua Yu Fang Yi Xue Za Zhi. 2017. PMID: 28592086. doi:10.3760/cma.j.issn.0253-9624.2017.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。